Leishmaniasis: Recognition and management with a focus on the immunocompromised patient

American Journal of Clinical Dermatology

Volumn 3, Issue 2, 2002, Pages 91-105

  Choi, C M ^a   Lerner, E A ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; ANTIPROTOZOAL AGENT; BCG VACCINE; CYTOKINE; DAPSONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERFERON; INTERLEUKIN 12; ITRACONAZOLE; KETOCONAZOLE; LEISHMANIA VACCINE; LIDOCAINE; LIVE VACCINE; LOCAL ANESTHETIC AGENT; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PLACEBO; PRILOCAINE; PROTOZOAL VACCINE; RIFAMPICIN; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNINDEXED DRUG; ZINC SULFATE;

ANIMAL MODEL; ARTHRALGIA; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOTHERAPY; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; ENDEMIC DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LEISHMANIA; LEISHMANIASIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MYALGIA; NONHUMAN; PANCREATITIS; PARASITE IDENTIFICATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTOZOAL INFECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN MANIFESTATION; VACCINATION; VIRUS INFECTION;

EID: 0036195689     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203020-00003     Document Type: Review

References (94)

1. Royal Society of Tropical Medicine and Hygiene, presidential address. Manson House, 15 October 1987. 'The little sister': A tale of Arabia
2. Evolution, classification and geographical distribution
3. Case records of the Massachusetts general hospital: A 21 year old woman with a persistent rash on the elbow after a sojourn in Central America (leishmaniasis)
4. Dissemination in cutaneous leishmaniasis, 3: Lymph node involvement
5. Dissemination in cutaneous leishmaniasis, 2: Satellite papules and subcutaneous induration
6. Dissemination in cutaneous leishmaniasis, 1: Subcutaneous nodules
7. Zoonotic cutaneous leishmaniasis in Saudi Arabia: Lesions healing naturally in man followed by a second infection with the same zymodeme of Leishmania major
8. Recurrent lesions in human Leishmania braziliensis infection: Reactivation or reinfection?
9. Endemic kala-azar in eastern Sudan: A longitudinal study on the incidence of clinical and subclinical infection and post kala-azar dermal leishmaniasis
10. Visceral leishmaniasis and post kala-azar dermal leishmaniasis
11. Sudan mucosal leishmaniasis
12. Mucosal leishmaniasis ('espundia' Escomel, 1911)
13. Cutaneous leishmaniasis: Review of 59 cases seen at the National Institutes of Health
14. American leishmaniasis
15. Cell-mediated immune response in Indian kala-azar and post kala-azar dermal leishmaniasis
16. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
17. Cutaneous scars in American tegumentary leishmaniasis patients: A site of leishmania (viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure
18. Visceral infection caused by leishmania tropica in veterans of Operation Desert Storm
19. Histopathology of cutaneous leishmaniasis
20. Cell populations in the lesion of human cutaneous leishmaniasis: A light microscopical, immunohistochemical and ultrastructural study
21. American cutaneous leishmaniasis: In situ characterization of the cellular immune response over time
22. Lymphocytes bearing antigen-specific gd T cell receptors accumulate in human infectious disease lesions
23. Transmission of Indian kala-azar to man by bites of phlebotomus argentipes, ann, and brun
24. Cutaneous leishmaniasis acquired during military service in the middle east
25. Congenital kala-azar and leishmaniasis in the placenta
26. Leishmania braziliensis infection of the nipple
27. Congenital kala-azar
28. Leishmaniasis epidemiology: All down to the DNA
29. Cytokine patterns in the pathogenesis of human leishmaniasis
30. Progressive disease or protective immunity to Leishmania major infection: The result of a network of stimulatory and inhibitory interactions
31. Host susceptibility factors to cutaneous leishmaniasis
32. Leishmaniasis
33. The role of interferon-g in the treatment of visceral and diffuse cutaneous leishmaniasis
34. Practical guide for the treatment of leishmaniasis
35. Leishmania donovani-reactive Th1-and Th2-like T cell clones from individuals who have recovered from visceral leishmaniasis
36. Immunomodulation of Chiclero's ulcer: Role of eosinophils, T cells, tumour necrosis factor and interleukin-2
37. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major
38. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major
39. The human immune response during cutaneous leishmaniasis: NO problem
40. Indications of the protective role of natural killer cells in human cutaneous leishmaniasis in an area of endemicity
41. Cutaneous leishmaniasis in rural Costa Rica
42. Monoclonal antibodies that distinguish subspecies of Leishmaniasis braziliensis
43. Demonstration of electrophoretic variation of two aminotransferases in leishmania
44. Diagnosis of New World leishmaniasis: Specific detection of species of the Leishmania braziliensis complex by amplification of kinetoplast DNA
45. Leishmania donovani: Intraspecific polymorphism of Sudanese isolates revealed by PCR-based analyses and DNA sequencing
46. Diagnosis of kala-azar by nested PCR based on amplification of the leishmania mini-exon gene
47. Detection and identification of leishmania DNA within naturally infected sand flies by seminested PCR on minicircle kinetoplastic DNA
48. Dermatofibroma parasitized by leishmania in HIV infection: A new morphologic expression of dermal Kala Azar in an immunodepressed patient
49. CD4+ and CD8+ T cell immune responses of immunocompetent and immunocompromised (AIDS) patients with American tegumentary leishmaniasis
50. Diffusely disseminated cutaneous Leishmania major infection in a child with acquired immunodeficiency syndrome
51. Visceral leishmaniasis in HIV-positive patients: Primary infection, reactivation and latent infection. Impact of CD4+ T-lymphocyte counts
52. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients
53. Disseminated American muco-cutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: A case report
54. American cutaneous leishmaniasis associated with HIV infection: Report of four cases
55. Performance of immunoblotting in diagnosis of visceral leishmaniasis in human immunodeficiency virus-leishmania sp.-coinfected patients
56. Leishmaniasis of the tongue in a renal transplant recipient
57. Post kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: Treatment with liposomal amphotericin B
58. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and leishmania, in an area of Madrid, Spain
59. Clinical manifestations of visceral leishmaniasis associated with HIV infection: A retrospective study of 91 French cases
60. Experimental pathogenicity of viscerotropic and dermotropic isolates of Leishmania infantum from immunocompromised and immunocompetent patients in a murine model
61. Leishmania and human immunodeficiency virus coinfection: The first 10 years
62. Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain
63. Mediterranean leishmaniasis in HIV-infected patients: Epidemiological, clinical, and diagnostic features of 22 cases
64. Report on the 8th European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland; 1997 May 25-28
65. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France
66. Short report: Occurrence of Leishmania donovani DNA in donated blood from seroreactive Brazilian blood donors
67. Rapid identification of causative species in patients with Old World leishmaniasis
68. Variability of Leishmania (Leishmania) infantum among stocks from immunocompromised, immunocompetent patients and dogs in Spain
69. Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1
70. Generalized cutaneous leishmaniasis in acquired immunodeficiency syndrome
71. Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies
72. Recommendations for treating leishmaniasis with sodium stibogluconate (pentostam) and review of pertinent clinical studies
73. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia
74. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: Report of 70 cases
75. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
76. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis: A randomized controlled trial
77. Placebo-controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala
78. Use of itraconazole in the treatment of mucocutaneous leishmaniasis: A pilot study
79. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis
80. Cutaneous leishmaniasis treated with controlled localized heating
81. Topical treatment of old world cutaneous leishmaniasis caused by Leishmania major: A double-blind control study
82. Cryosurgery in cutaneous leishmaniasis
83. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis
84. Miltefosine, and oral agent, for the treatment of Indian visceral leishmaniasis
85. Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis
86. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1 infected patients
87. Vaccines for parasitic diseases
88. Leishmanization in the Islamic Republic of Iran
89. American cutaneous leishmaniasis in U.S. travelers
90. Vaccine development against cutaneous leishmaniasis: Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge
91. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: A randomized controlled trial
92. Toward a defined anti-Leishmania vaccine targeting vector antigens: Characterization of a protective salivary protein